NeuroBo Pharmaceuticals (NRBO) announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to “MetaVia (MTVA) Inc.,” which will be effective on November 29, 2024. In parallel, the Company’s common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, “MTVA,” which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, and a new company logo, on the Effective Date.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals Completes Phase 2a Trial for MASH Drug
- NeuroBo Pharmaceuticals completes last patient visit in Phase 2a DA-1241 trial
- NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation
- NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1
- NeuroBo Pharmaceuticals announces data from SAD Part 1 of trial of DA-1726